An observational study in Sellar Mass and Pituitray Tumor, sponsored by Arab Board of Neurosurgery. Completed at 1 site in Yemen. Open to participants aged 11 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Arab Board of Neurosurgery · Observational
The goal of this observational study is to learn about the clinical spectrum of sellar masses, aiming to understand the correlation between the imaging features and the future surgical approach and histopathology results.
The main question it aims to answer is:
Does being both LMIC and conflict country change the global data!? Participants were included during a period of 3 years in a governmental hospital TMGH.
This is the only study on the registry with Arab Board of Neurosurgery as lead sponsor.
Counted across the registry records on this site, refreshed daily.
included all Patients presenting with sellar region masses from December 2022 to December 2025, at Neurosurgical department at TMGH
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients withe age of 11 to 65, who was diagnosed with sellar mass using MRI, and get treated surgically
Procedure: Craniectomy
Bicoronal vs. Pterional approach vs endoscopic
Correlation between pre-operative radiological features and definitive histopathological diagnosis.
To evaluate the diagnostic accuracy of pre-operative magnetic resonance imaging (MRI) by determining the percentage of cases where pre-operative radiological features match the definitive post-operative histopathological classification (e.g., pituitary adenoma, craniopharyngioma, meningioma).
Time frame: 3 years
Plan to share: Undecided — Individual participant data will not be shared publicly to protect patient confidentiality and privacy. The informed consent obtained from the participants covers the publication of aggregated study findings within the manuscript and tables only, and does not include explicit permission for the public disclosure of raw, de-identified individual clinical or radiological datasets."
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.